<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00065715</url>
  </required_header>
  <id_info>
    <org_study_id>R01AT001428</org_study_id>
    <secondary_id>R01AT001428</secondary_id>
    <secondary_id>BarrettB</secondary_id>
    <nct_id>NCT00065715</nct_id>
  </id_info>
  <brief_title>Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo)</brief_title>
  <acronym>PEP</acronym>
  <official_title>Placebo: Physician or Pill? A Randomized Trial in a Common Cold Model Funded by NIH NCCAM Under RFA &quot;The Placebo Effect in Clinical Practice&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The design and interpretation of randomized trials is intimately connected to the use of
      &quot;placebo&quot;. The nature and magnitude of placebo effects, however, is very poorly understood.
      This study will assess and compare placebo effects and physician interaction effects within a
      community-acquired common cold model. The goal of this study is to assess two kinds of
      placebo affects and how physician interaction effects;

        1. The effect of receiving blinded placebo, compared to no treatment; and

        2. The effect of receiving open-label active Echinacea treatment compared to blinded active
           treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As per Brief Summary
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration and severity of illness, as assessed by the Wisconsin Upper Respiratory Symptom Survey (WURSS-21)</measure>
    <time_frame>twice daily during illness</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>SF-8 general health-related quality of life</measure>
    <time_frame>daily during illness</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>perceived stress PSS-4</measure>
    <time_frame>daily during illness</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>optimism LOT</measure>
    <time_frame>two days after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient satisfaction CARE</measure>
    <time_frame>after doctor patient interaction</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>feeling thermometer - EuroQol VAS</measure>
    <time_frame>daily during illness</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IL-8 (inflammatory cytokine)from nasal wash</measure>
    <time_frame>2 days after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neutrophil count from nasal wash</measure>
    <time_frame>two days after enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">719</enrollment>
  <condition>Common Cold</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No pills</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Blinded placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Echinacea - Blinded</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Echinacea - Unblinded, Open Label</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Echinacea</intervention_name>
    <description>Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. B) Echinacea angustifolia - 600 mg root yields 150 mg dried extract, standardized to contain 2.0 mg alkamides. Each batch of tablets is analyzed by Reversed Phase - High Peformance Liquid Chromatography to determine the levels of alkamides and caffeic derivatives present. Caffeic acid derivative levels are typically as follows: caftaric acid = 0.5 to 2.0 mg/tablet; cichoric acid = 3.4 to 8.5 mg/tablet; chlorogenic acid = &lt; 0.5 mg/tablet; dicaffeoyl quinic acids (including cynarin) = 0.7 to 2.0 mg/tablet; echinacoside = 1.0 to 1.7 mg/tablet</description>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blinded placebo</intervention_name>
    <description>Blinded placebo - Coated tablet</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Suspected or known cold

          -  At least one of the following cold symptoms:

        nasal discharge, nasal congestion, sneezing, or sore throat

          -  Enrolled in school, for children 12 to 17 years of age

        Exclusion criteria:

          -  Pregnancy;

          -  Symptom duration &gt; 36 hrs

          -  Concurrent use of antibiotics, antivirals, nasal steroids, decongestants or
             antihistamines;

          -  Anticipated need for symptom-relieving meds during cold

          -  Autoimmune/deficiency disease

          -  History of allergic rhinitis with current eye itching/sneezing

          -  History of asthma w/current cough/SOB

          -  Prior study entry

          -  Allergy to Echinacea
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce Barrett, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin-Madison Department of Family Medicine</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53706-1490</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fammed.wisc.edu</url>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2003</study_first_submitted>
  <study_first_submitted_qc>July 31, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2003</study_first_posted>
  <last_update_submitted>December 3, 2014</last_update_submitted>
  <last_update_submitted_qc>December 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>head cold</keyword>
  <keyword>common cold</keyword>
  <keyword>echinacea</keyword>
  <keyword>placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Common Cold</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

